Navigation Links
Plandai Biotechnology, Inc. Announces Formation Of New Entity To Develop Pharmaceutical Applications

SEATTLE, May 7, 2013 /PRNewswire/ -- Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the formation of Phyto Pharmacare, Inc., a Delaware corporation, which will oversee all aspects of developing and marketing Phytofare™ extracts for pharmaceutical and drug applications.

Plandai Chief Executive Officer Roger Duffield commented, "As a management team, we felt it necessary to differentiate the purely pharmaceutical operations from our farming, production and nutraceutical business. Taking our Phytofare™ extracts and seeking FDA clearance to market them to treat specific diseases brings unique challenges and requires an entirely different focus. The creation of Phyto Pharmacare, which will operate under a license from Plandai, enables that division to focus on specific drug targets and take our products through the various stages of clinical trials and FDA approval."

Initially, Phyto Pharmacare will focus on using its Phytofare™ Catechin Extract as both a cure for and prevention of malaria.  Malaria is a parasite infection transmitted by mosquitoes and primarily located in sub-Sahara Africa and southern Asia, where it results in nearly a million deaths annually. 

Mr. Duffield explained, "Malaria is one of great plagues that still kills way too many people, most of whom are children and the elderly located in some of the poorest and most remote areas of the world where access to life-saving medicine is either unaffordable or unavailable.  With drug-resistant strains of the parasite now spreading across Asia, we could soon be facing a pandemic.  The catechins found in green tea are well documented for their anti-malarial properties, but low human bioavailability (absorption) has limited its effectiveness as a drug.  We believe that the high bioavailability of our Phytofare™ extract will finally yield a suitable drug for treating not only malaria but also other blood-borne parasitic infections."

Phyto Pharmacare will shortly begin validating the bioavailability of Phytofare™ Catechin Extract in human studies and is just completing in-vitro studies of its anti-malarial properties compared against other catechin extracts at St. George's University of London in England. 

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.  Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.  Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.  For more information, please visit

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Andrew Beyer
Phone: 619-202-7456

SOURCE Plandai Biotechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AMRI Announces First Quarter 2013 Results and Raises EPS Guidance for the Year
2. Rigel Announces First Quarter 2013 Financial Results
3. Mindray Announces First Quarter 2013 Financial Results
4. Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
5. Hologic Announces Second Quarter Fiscal 2013 Operating Results
6. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
7. AG Mednet Announces Partnership with The Methodist DeBakey Heart & Vascular Center Echocardiography Core Lab
8. Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
9. Apollo Medical Holdings Announces Record Fiscal Year-End Results
10. Atrium Medical Announces 1-year results of the INFUSE-AMI Trial
11. Premier Home Medical Supply Vendor Med Supply Shop Announces Drive Spring Promotion
Post Your Comments:
(Date:10/13/2015)...  Vitamin Angels – a charity that distributes vitamins ... nutritional support - announced its work continues to support ... The UN,s newly established Global Goals - announced on ... up to the Millennium Development Goals established in 2000 ... 17 Global Goals intend to address three primary objectives: ...
(Date:10/13/2015)... -- A minimally-invasive treatment just became available to men suffering ... than 10 years of clinical trials, the Food and ... High Intensity Focused Ultrasound (HIFU), a procedure that can ... and minimizing chances for erectile and urinary dysfunction associated ... pioneering Miami urologist who spearheaded ...
(Date:10/13/2015)... 13, 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization of ... its previously announced underwritten public offering of 5,000,000 ... purchase up to 3,000,000 shares of the Company,s ... the public of $3.00. The shares of common ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... Sir Grout of ... to the local Boston chapter of Ronald McDonald House Charities® (RMHC®). This donation was ... supported Sir Grout of Greater Boston since its inception. , “We believe strongly in ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... of anesthesia and pain management services, today announced its partnership with WPC ... integrates data from disparate systems and organizes the data into an aggregated data ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to ... Summit and NAVUG Summit are independent user conferences designed and led by users ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology company ... a significant contract that will provide its award-winning private messaging solution to Independence ... growing success of its Relay program, IBX Wire™, which now has over 550,000 ...
(Date:10/13/2015)... ... October 13, 2015 , ... A child without a healthy ... SmileCareClub , the leading remote invisible aligner system, has joined with Global Dental ... without it. For each aligner treatment plan purchased, SmileCareClub will donate one clinic visit ...
Breaking Medicine News(10 mins):